Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis

Jolijn R van Leeuwen1 Center of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases (LuVaCs), Department of Internal Medicine - Nephrology Section, Leiden University Medical Center, Leiden, the Netherlands

https://orcid.org/0000-0001-9341-7566

Tamara Popov2 Vifor Pharma Ltd, Glattbrugg, Switzerland

Achim Obergfell2 Vifor Pharma Ltd, Glattbrugg, Switzerland

Ton J Rabelink1 Center of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases (LuVaCs), Department of Internal Medicine - Nephrology Section, Leiden University Medical Center, Leiden, the Netherlands

YK Onno Teng1 Center of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases (LuVaCs), Department of Internal Medicine - Nephrology Section, Leiden University Medical Center, Leiden, the NetherlandsCorrespondence[email protected]

https://orcid.org/0000-0001-9920-2195

References

Yates M, Watts R. ANCA-associated vasculitis. Clin Med. 2017;17(1):60–64. doi:10.7861/clinmedicine.17-1-60
PubMed Web of Science ®Google Scholar
Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756–2767. doi:10.1681/ASN.2016111179
PubMed Web of Science ®Google Scholar
Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599–609. doi:10.1056/NEJMoa2023386
PubMed Web of Science ®Google Scholar
Vifor Pharma press releases. VFMCRP receives EU approval for Tavneos® for the treatment of ANCA associated vasculitis; 2022. Available from: https://www.viforpharma.com/sites/vifor-corp/files/media/vifor-pharma-press-release-tavneos-granted-eu-approval-190122.pdf. Accessed October 6, 2022.
Google Scholar
van Leeuwen JR, Bredewold OW, van Dam LS, et al. Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep. 2022;7(3):624–628. doi:10.1016/j.ekir.2021.11.036
PubMed Web of Science ®Google Scholar
Gabilan C, Pfirmann P, Ribes D, et al. Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option. Kidney Int Rep. 2022;7(5):1115–1118. doi:10.1016/j.ekir.2022.01.1065
PubMedGoogle Scholar
Merkel PA, Niles J, Jimenez R, et al. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 2020;2(11):662–671. doi:10.1002/acr2.11185
PubMedGoogle Scholar

Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date